Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Dalteparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thromboembolism 13 Venous Thrombosis 10 Neoplasms 9 Pulmonary Embolism 7 Thromboembolism 4 Thrombosis 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Lung Neoplasms 3 Neoplasm Metastasis 2 Lymphoma 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Thrombocytopenia 1 Thrombocythemia, Essential 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Ovarian Neoplasms 1 Obesity 1 Neoplasms, Plasma Cell 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Carboplatin 274 Paclitaxel 273 Bevacizumab 148 liposomal doxorubicin 86 pembrolizumab 84 Gemcitabine 82 Cyclophosphamide 81 olaparib 79 Cisplatin 75 Topotecan 72 niraparib 59 Docetaxel 49 Doxorubicin 44 Drug Therapy 38 fludarabine 35 Taxes 35 Nivolumab 32 Filgrastim 31 Specimen Handling 29 Etoposide 28 Surveys and Questionnaires 27 Magnetic Resonance Spectroscopy 27 Hyperthermic Intraperitoneal Chemotherapy 27 Peripheral Blood Stem Cell Transplantation 23 durvalumab 21 Immunoglobulin G 21 Disulfides 21 Cytoreduction Surgical Procedures 21 Blood Specimen Collection 21 Biopsy 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00239980 2010-02-03

Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)

Ontario Clinical Oncology Group (OCOG)

Phase 2 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡